Ivermectin & Cancer Research with proposed Hybrid Orthomolecular Protocol Journal of ANTIBIOTICS: https://www.nature.com/articles/ja201711 Title: “Ivermectin: enigmatic multifaceted “wonder” drug continues to surprise and exceed expectations” Published: Feb 15, 2017 Abstract Over the past decade, the global scientific community have begun to recognize the unmatched value of an extraordinary drug, ivermectin, that originates from a single microbe unearthed from soil in Japan. Work on ivermectin has seen its discoverer, Satoshi Ōmura, of Tokyo’s prestigious Kitasato Institute, receive the 2014 Gairdner Global Health Award and the 2015 Nobel Prize in Physiology or Medicine, which he shared with a collaborating partner in the discovery and development of the drug, William Campbell of Merck & Co. Incorporated. Today, ivermectin is continuing to surprise and excite scientists, offering more and more promise to help improve global public health by treating a diverse range of diseases, with its unexpected potential as an antibacterial, antiviral and anti-cancer agent being particularly extraordinary. Quote in the article: “Since the prodigious drug donation operation began, 1.5 billion treatments have been approved.” Disease-fighting potential identified to date (Feb 15, 2017) listed in the article: Myiasis Trichinosis Disease vector control – toxic to 84 species of insections Malaria Leishmaniasis African trypanosomiasis (sleeping sickness) American trypanosomiasis (Chagas disease) Schistosomiasis Bedbugs Rosacea Asthma Epilepsy Neurological disease Antiviral (e.g. HIV, dengue, encephalitis) Antibacterial (tuberculosis and Buruli ulcer) Anti-cancer “shown to exhibit both anti-cancer and anti-cancer stem cell properties” In human ovarian cancer and NF2 tumor cell lines, high-dose ivermectin inactivates protein kinase PAK1 and blocks PAK1dependent growth. .. PAK1 is essential for the growth of more than 70% of all human cancers, including breast, prostate, pancreatic, colon , gastric, lung, cervical and thyroid cancers, as well as hepatoma, glioma, melanoma, multiple myeloma and for neurofibromatosis tumors.” Ivermectin suppresses breast cancer by activating cytostatic autophagy, disrupting cellular signaling in the process, probably by reducing PAK1 expression… It has been reported that ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells and it has also been suggested that ivermectin synergizes with the chemotherapy agents cytarabine and daunorubicin to induce cell death in leukemia cells, with researchers claiming that ivermectin could be rapidly advanced into clinical trials. Cancer stem cells are a key factor in cancer cells developing resistance to chemotherapies and these results indicate that a combination of chemotherapy agents plus ivermectin could potentially target and kill cancer stem cells, a paramount goal in overcoming cancer. Ivermectin inhibits proliferation and increases apoptosis of various human cancers. Again, given that ivermectin is already approved for use in humans, its rapid development as an anti-mitotic agent offers significant promise.
Issuu converts static files into: and more. Sign up and create your flipbook.